COMMUNIQUÉS West-GlobeNewswire

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
18/05/2026
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved [...]
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
18/05/2026
Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE, Tenn., May 18, 2026 [...]
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
18/05/2026
Gene therapy and rare disease leader with nearly two decades of drug development experience to focus on advancing the company’s next-generation gene editing pipeline CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- [...]
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
18/05/2026
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to [...]
Novastra Therapeutics Appoints Chief Financial Officer as Company Advances Lead Candidate Toward Global Clinical Development
18/05/2026
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics , a clinical-stage biotech company developing a novel category of cancer immune therapy, today announced the appointment of Jarett Poll as [...]
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
18/05/2026
WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced [...]
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05/2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
18/05/2026
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron ® 4-week [...]
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
18/05/2026
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
18/05/2026
New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of age The data shows that 85 [...]
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
18/05/2026
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18/05/2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics [...]
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
18/05/2026
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological [...]
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
18/05/2026
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18/05/2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
18/05/2026
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
18/05/2026
KING OF PRUSSIA, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, today announced that it will [...]

Pages